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Strengths and limitations of this study
 ► PLACEMENT comprises a comprehensive feasibili-
ty study, where all aspects of an effectiveness trial 
have been undertaken including multicentre recruit-
ment, randomisation, data collection and follow- up.
 ► In addition, we have performed qualitative stud-
ies to assess barriers to recruitment, developed a 
framework for a pragmatic economic evaluation and 
identified a suitable strategy for measuring postop-
erative pain.
 ► Limitations of the study are that it lacks the power 
to assess the effectiveness of the intervention based 
on this feasibility study alone, and it does not assess 
the use of a placebo arm.
AbStrACt
Objectives To determine the feasibility of undertaking 
a randomised controlled effectiveness trial evaluating 
the use of a perineural catheter (PNC) after major lower 
limb amputation with postoperative pain as the primary 
outcome.
Design Randomised controlled feasibility trial.
Setting Two vascular Centres in South Wales, UK.
Participants 50 patients scheduled for major lower limb 
amputation (below or above knee) for complications of 
peripheral vascular disease.
Interventions The treatment arm received a PNC placed 
adjacent to the sciatic or tibial nerve at the time of surgery, 
with continuous infusion of levobupivacaine hydrochloride 
0.125% for up to 5 days. The control arm received neither 
local anaesthetic nor PNC. Both arms received usual 
perioperative anaesthesia and postoperative analgesia.
Primary and secondary outcome measures The 
primary outcomes were the proportion of eligible patients 
who were randomised and the proportion of recruited 
patients who provided primary effectiveness outcome 
data. Secondary outcomes were: the proportion of 
recruited patients reaching 2 and 6 month follow- up and 
supplying pain data; identification of key cost drivers; 
development of an economic analysis framework for 
a future effectiveness trial; identification of barriers to 
recruitment and site set- up; and identification of the best 
way to measure postoperative pain.
results Seventy- six of 103 screened patients were 
deemed eligible over a 10 month period. Fifty (64.5%) of 
these patients were randomised, with one excluded in the 
perioperative period. Forty- five (91.3%) of 49 recruited 
patients provided enough pain scores on a 4- point verbal 
rating scale to allow primary effectiveness outcome 
evaluation. Attrition rates were high; 18 patients supplied 
data at 6 month follow- up. Costs were dominated by length 
of hospital stay. Patients and healthcare professionals 
reported that trial processes were acceptable.
Conclusions Recruitment of patients into a trial 
comparing PNC use to usual care after major lower limb 
amputation with postoperative pain measured on a 4- point 
verbal rating scale is feasible. Evaluation of longer- term 
symptoms is difficult.
trial registration number ISRCTN: 85 710 690. EudraCT: 
2016-003544-37.
bACkgrOunD
Despite advances in peripheral revascular-
isation, 1% to 2% of patients with periph-
eral arterial disease (PAD) undergo major 
lower limb amputation.1 2 Postoperatively, 
many amputees experience acute pain, and 
in the long- term chronic stump pain (CSP) 
and phantom limb pain (PLP) can affect as 
many as 80% of patients.3 4 Treating both 
acute and chronic pain is difficult,5 and there 
is some evidence that suboptimal control 
of perioperative pain may increase rates of 
PLP or CSP.4 6 The UK National Confidential 
Enquiry into Patient Outcome and Deaths 
review of lower limb amputations found that 
epidural or intravenous patient controlled 
opioid analgesia were the most commonly 
employed methods of managing analgesia 
postoperatively, but that only 37% of patients 
experienced good acute pain control.7 While 
opioids may provide good analgesia, they 
copyright.
 o
n
 January 3, 2020 at Cardiff University. Protected by
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2019-029233 on 11 November 2019. Downloaded from 
2 Bosanquet DC, et al. BMJ Open 2019;9:e029233. doi:10.1136/bmjopen-2019-029233
Open access 
have associated side effects, including nausea, vomiting,8 
constipation,9 sedation and pruritus.10 Their use has also 
been shown to increase both hospital costs and length of 
stay.11 12 Lumbar spinal epidural anaesthesia is likely to be 
the optimal strategy for managing postoperative pain in 
this cohort.13–15 However, due to use of anticoagulants or 
antiplatelet agents, or the presence of an active infection, 
epidural anaesthesia is contraindicated over 60% of the 
time.15
The use of perioperative and postoperative local 
anaesthetic infiltration and infusion to the surgical site 
is recognised as a useful adjunct in postoperative pain 
relief.16 Peripheral wound catheters (PWCs) are thin 
catheters placed at the time of surgery in the surgical 
field, of which perineural catheters (PNCs) are a specific 
type, placed adjacent to major nerves. A continuous infu-
sion of local anaesthetic can thus be delivered directly to 
the perineural space.17 PWC usage has been associated 
with improved pain scores, reduced opioid use, reduced 
length of hospital stay and increased patient satisfaction,18 
with few adverse events.19 20
PNCs have been used for major amputations, inserted 
adjacent to either the sciatic or tibial nerve (for above 
knee amputations (AKAs) or below knee amputations 
(BKAs), respectively), since at least 1991.21 A systematic 
review of PNC use in lower limb amputation showed 
patients receiving a PNC required less opioid anal-
gesia compared with controls, although no significant 
difference was noted in pain scores.22 However, the 
quality of included papers was low, studies were small 
and comparison groups were non- standardised. Other 
papers excluded from the meta- analysis or published 
in the interim have generally suggested that PNCs 
reduce postoperative pain.23–27 During trial set- up we 
performed a survey of vascular Centres in the UK which 
demonstrated that almost exactly half of surveyed 
centres were using PNCs ‘most of the time’ or ‘all of 
the time’, suggesting there was equipoise within the 
vascular community as a whole regarding their value in 
amputees.
While there are limited data to suggest PNCs are bene-
ficial in reducing postoperative pain and opioid use, the 
overall quality of evidence is very low, making a contem-
poraneous randomised controlled trial (RCT) necessary 
to establish its value in pain relief, opioid use, quality of 
life (QoL)28 and overall cost. Given the very low- quality 
evidence available, a feasibility study was deemed a 
necessary first step in order to inform trial design and 
sample size calculation. The PLACEMENT trial was thus 
designed as a parallel group, randomised controlled 
feasibility study to assess the feasibility of conducting an 
effectiveness trial evaluating PNC insertion with a contin-
uous local anaesthetic infusion, inserted at the time of 
amputation, on short and medium term postoperative 
outcomes.29
MAterIAlS AnD MethODS
trial design
PLACEMENT was a pragmatic randomised unblinded 
1:1 feasibility study, undertaken at the Royal Gwent 
Hospital, Aneurin Bevan University Health Board and 
Morriston Hospital, Abertawe Bro Morgannwg University 
Health Board, Wales. The protocol is available as a online 
Supplementary File. The study is reported in line with 
Consolidated Standards of Reporting Trials guidelines.30 
Fifty adult patients undergoing major lower limb amputa-
tion, either BKA or AKA were randomised to receive the 
intervention, described below, or usual care.
Inclusion and exclusion criteria
Patients were suitable for inclusion if they were aged 18 
years or older, undergoing elective or emergency BKA or 
AKA for complications of PAD, were able to assess pain 
using a Verbal Rating Scale (VRS), and (for women of 
childbearing potential) were willing to undergo a preg-
nancy test before the trial and agree to either use a highly 
effective method of contraception or abstain from sexual 
intercourse until at least 7 days after their amputation. 
Patients with a life expectancy of greater than 2 weeks 
were suitable, which was done to minimise early patient 
attrition in those deemed very high risk for surgery.
Patients undergoing digital, metatarsal, tarsal or 
through knee amputation, disarticulation of the hip, 
hindquarter amputation or simultaneous bilateral ampu-
tations were excluded. Patients unable to provide consent 
due to incapacity (as defined by the Mental Capacity 
Act 2005), and vulnerable or protected adults, were 
excluded. Patients with an allergy or intolerance to any 
of the substances in the PNC, or local anaesthetic agents, 
or chronically taking class IB anti- arrhythmic agents or 
local anaesthetic agents, were excluded, as were preg-
nant females and patients expected to be managed in the 
intensive care unit (ICU) postoperatively and be sedated 
for more than 24 hours. Patients undergoing more than 
one major amputation were not permitted to be enrolled 
twice.
In addition, patients who were initially eligible for 
PLACEMENT could become ineligible if the major 
amputation was not performed, the appropriate nerve 
was not identified or if due to perioperative or intraop-
erative instability, the patient required admission to the 
ICU and was likely to be sedated for more than 24 hours, 
or not expected to survive more than 2 weeks.
trial procedures
Intervention arm
Participants randomised to the treatment arm received 
a PNC placed at the time of the amputation (either 
to the sciatic or tibial nerve) with a continuous infu-
sion of levobupivacaine hydrochloride 0.125% (2.5 
to 15 mg/hour) for up to 5 days, in addition to usual 
care (described below). All surgeons were assessed and 
trained prior to trial enrolment to ensure PNC placement 
was standardised. During the amputation the nerve was 
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identified. An epidural catheter tube was used as the PNC 
and placed via a Tuohy needle in the perineural space 
to ensure that the tip lay 10 to 20 cm cranially from the 
amputated end. The catheter end was removed through 
the skin distant to the wound edge and secured. Division 
of the nerve was then performed under tension.
Local anaesthetic infusion was delivered via an elas-
tomeric pump (AutoFuser, ACE Medical, Korea), and 
started in the immediate postoperative period, with stan-
dard monitoring of the pump by trained ward nursing 
staff and members of the acute pain team, as per local 
hospital policy.
Control arm
Participants randomised to the control arm received 
usual care. This consisted of standard anaesthetic and 
postoperative analgesia, with daily review by a specialist 
pain team. Preoperative epidural analgesia, spinal anal-
gesia, regional nerve blocks or PWCs were permitted in 
either arm. Patient- controlled analgesia was used when 
appropriate after discussion with patients. Patients were 
cared for by ward staff familiar with patient- controlled 
analgesia and use of the elastomeric pump.
Qualitative assessment of trial processes and patient 
experience
In order to evaluate trial processes and acceptability of 
the intervention, semi- structured interviews were under-
taken to explore the experiences of trial participants and 
health professionals. Interviews were conducted by expe-
rienced qualitative health researchers (SM, MM, HS) who 
were not involved in the delivery of the trial.
Twenty semi- structured interviews were conducted 
with 14 trial participants (seven in the intervention 
arm, seven in the control arm) purposefully sampled to 
include participants at both study sites, from both arms 
of the trial, while also taking into consideration varia-
tion in gender, age and amputation type (below and 
above knee). Interviews were carried out at two time 
points; interview 1 within the postoperative period and 
up to 1 month following amputation (n=10); interview 2 
between 6 and 16 months following amputation (n=10). 
Six participants completed an interview at both time 
points (forming paired interviews). Interviews with trial 
participants took place between May 2017 to July 2018 
and explored patients’ experiences and perceptions of 
postoperative pain management, together with under-
standing and acceptability of trial processes. Interviews 
were also conducted with 10 health professionals directly 
involved in the trial and purposefully sampled to include 
variation in role (eg, vascular surgeons, research nurses, 
etc) and representation across both study sites. Inter-
views took place between February 2018 to April 2018 
and focused on the delivery of the intervention in the 
real healthcare setting, exploring fidelity, feasibility and 
acceptability. Topic guides were developed by the qual-
itative researchers, discussed within the Trial Manage-
ment Group (TMG) and reviewed again following early 
interviews. All interviews were audio recorded with the 
permission of the interviewee, transcribed verbatim, 
anonymised and uploaded to NVivo 11 for analysis. A 
systematic five- stage framework approach was used in 
order to facilitate exploration and comparison of the data 
across cases and themes. The first three stages ‘familiari-
sation with data’, ‘identifying a thematic framework’ and 
‘indexing’, are common to other forms of qualitative anal-
ysis. The fourth stage, ‘charting’, involves retrieving the 
coded data and producing summaries of interviewees’ talk 
on each theme and visually arranging it in a table to build 
an overall picture of the whole data set. The fifth stage, 
‘mapping’, involves using the charts to map and inter-
pret the data set as a whole and connect with the original 
research objectives. SM developed a thematic framework 
using a deductive approach to incorporate the research 
objectives and topic guide, and an inductive approach to 
ensure that new themes, which had not been pre- empted 
and initiated from the participants themselves, were iden-
tified in the data. The thematic framework was developed 
and revised after regular discussion with LB- H. Tran-
scripts were double- coded until consensus was reached 
through regular discussion to enhance analytic reliability 
and validity.
Outcomes
Feasibility outcomes
As a feasibility study, the primary outcomes were designed 
to assess if running an effectiveness trial investigating the 
effect of PNC placement with local anaesthetic infusion 
on immediate postoperative pain is possible and appro-
priate, and to establish the best way to undertake such 
a trial. The primary outcomes were therefore concerned 
with patient recruitment and outcome assessment.
 ► The primary recruitment outcome was the propor-
tion of eligible patients who were recruited.
 ► The primary assessment outcome was the proportion 
of recruited patients who provided adequate putative 
primary effectiveness outcome data, using the various 
methods of postoperative pain assessment (see below).
Secondary outcomes included:
 ► Recruitment and retention – the proportion of eligible 
patients who provided informed consent; the propor-
tion of those recruited who reached 2 and 6 month 
follow- up; the overall time to complete recruitment.
 ► Assessment of pain – identify appropriate methods 
and tools for collecting postoperative pain data.
 ► Sample size calculation – sample size estimation for a 
future effectiveness trial, based on effect size estimates.
 ► Secondary outcome assessment – identify what 
secondary outcome measures (both short- term and 
long- term measures) are important, and how best to 
assess them.
 ► Economic evaluation – identify key cost drivers and 
develop a robust framework for economic evaluation 
in a future effectiveness trial.
 ► Trial management and quality control – evaluation of 
trial processes, from site set- up to final data collection, 
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as detailed in the ‘Qualitative assessment of trial 
processes and patient experience’ section above.
 ► Patient experience – develop a greater understanding 
of patient experience of pain and pain management, 
and the experience of being enrolled in the trial, 
as detailed in the ‘Qualitative assessment of trial 
processes and patient experience’ section above.
Effectiveness outcomes
Effectiveness outcomes were defined to provide a 
template for a future effectiveness trial.
Primary effectiveness outcome
One of the secondary feasibility outcomes of the study 
was to identify appropriate methods and tools to assess 
postoperative pain. We therefore defined two alternative 
primary effectiveness outcomes, according to which tool 
was found to be the most appropriate.
First, we collected pain scores on an 11- point (0 to 10) 
VRS, whenever suitably trained personnel were available, 
up to three times a day, with at least 4 hours between 
pain measurements, for the first five postoperative days.31 
Second, we transformed any recorded 11- point VRS to a 
4- point VRS (0 to 3; none/mild/moderate/severe) using 
a published algorithm32 and supplemented these with 
any 4- point VRS recorded on the routine nursing obser-
vations chart (the standard way of measuring pain in both 
trial centres) at times where there was no 11- point pain 
score available. The maximum potential pain recordings 
available were 17 (two from day of surgery, and three 
from the following 5 days).
The principle primary outcome was defined as the 
median 11- point VRS if at least nine pain scores were 
recorded, and ‘missing’ otherwise. This decision, taken by 
the TMG, and subsequently ratified ty the Trial Steering 
Committee (TSC), was to include all patient data records 
if more than 50% of possible pain score data points were 
reported. The alternative primary outcome was defined 
as the modal 4- point VRS if at least nine pain scores were 
recorded, and ‘missing’ otherwise.
Secondary effectiveness outcomes
The following secondary effectiveness outcomes were 
captured:
 ► Overall Benefit of Analgesia Score (OBAS)33 preoper-
atively and once daily postoperatively for 5 days.
 ► Self- completed Leeds Assessment of Neuropathic 
Symptoms and Signs scores (S- LANSS)34 preopera-
tively and on postoperative day 5.
 ► Analgesia ‘Treatment failure’, defined as an 11- point 
VRS ≥4, or 4- point VRS of ‘Moderate’ or ‘Severe’ 
during the first 5 postoperative days
 ► Opioid use measured preoperatively and once daily 
postoperatively for 5 days, converted to morphine 
equivalents.
 ► Incidence of nausea or vomiting during the total inpa-
tient stay.
 ► Pain assessed by S- LANSS at 2 and 6 month follow- up.
 ► PLP and CSP as assessed by the Groningen question-
naire35 at 2 and 6 month follow- up.
 ► Health- related QoL assessed using EQ- 5D- 5L and 
Hospital Anxiety and Depression Scale (HADS; 
reported as both anxiety and depression scores) 
preoperatively, at 2 and 6 month follow- up.
 ► Surgical site infection (SSI) rates classified as per the 
2008 CDC/NHSN (Centers forDisease Control and 
Prevention/National Healthcare Safety Network) 
document.
 ► Rate of successful identification of the nerve and PNC 
placement, as determined by the operating surgeon at 
the time of amputation.
 ► Resource usage during the first six postoperative 
months.
randomisation
Patients were randomised preoperatively or (prefer-
ably) intraoperatively. If preoperative randomisation 
was performed, the allocation was concealed from the 
surgeon and anaesthetist until the nerve was identified. 
Preoperative randomisation was only undertaken if 
the (unscrubbed) theatre staff were unable to perform 
the randomisation procedure. In this instance a single 
member of the unscrubbed theatre team completed 
the randomisation and recorded the outcome. Once 
the nerve was identified, the randomisation was given 
to the team. Randomisation was performed via a web- 
based remote randomisation programme, with telephone 
backup during working hours. Randomisation was mini-
mised according to level of amputation (AKA vs BKA) 
and sex, and stratified by site.
blinding
No individuals included in the study, including patients, 
surgeons, anaesthetists, nursing staff, outcome assessors 
or other healthcare professionals, were blinded in the 
study.
Sample size
The trial was designed to assess feasibility, rather than 
effectiveness, and a convenience sample of 50 patients 
was determined appropriate. Both primary feasibility 
outcomes were proportions, and this sample size allows 
for a total proportion to be conservatively estimated at 
50% (ie, 25 out of 50) to within plus or minus 13.9% 
using a 95% CI.
Follow-up
Patients were contacted at 2 months (+/-2 weeks) and 6 
months (+/-1 month) for follow- up, preferably via tele-
phone. An experienced research nurse checked the 
hospital database to ensure the patient was not deceased, 
or an inpatient, prior to attempting contact. If the patient 
was unavailable or the phone call was unanswered, two 
further attempts were made to contact the patient after 2 
to 7 days. Non- responders had questionnaires posted to 
them with a stamped addressed envelope for return.
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Data captured at 2 and 6 months follow- up included 
data on PLP, CSP, neuropathic pain (S- LANSS), anxiety 
and depression (HADS), health- related quality of life 
(EQ- 5D) and patient- reported healthcare resource usage. 
The Groningen questionnaire was used to capture data 
on CSP and PLP. The Groningen questionnaire provides 
continuous data on symptom burden, but with no stan-
dardised methods of dichotomising its presence or 
absence. A consensus was reached by the Trial Manage-
ment Group to dichotomise patients into having CSP or 
PLP or not, depending on the results of the following 
questions. For CSP, we reviewed answers to the question: 
‘In the last 6 weeks/months since your amputation, how 
often did your stump hurt badly enough to keep you from 
doing things you wanted to do?’. For PLP, we reviewedan-
swers to the question: ‘In the last 6 weeks/months since 
your amputation, how often did your phantom hurt badly 
enough to keep you from doing things you wanted to 
do?’. A result of ‘every day’ or ‘once per week’ was consid-
ered as CSP or PLP, respectively, and a result of ‘every 
two weeks’, ‘once per month’, ‘less than once per month’ 
and ‘never’ was considered as no CSP or PLP, respectively.
Management of adverse events
Adverse events were defined and reported according to 
the Medicines for Human Use (Clinical Trials) Regula-
tions 2004 (SI2004/1031) and the subsequent amend-
ment regulations (SI2006/1938) and reported and 
actioned as per Good Clinical Practice (GCP). These 
included infection around the PNC exit site and toxicity 
reactions.
Adverse events that are recognised complications of 
major lower limb amputation were also collected, such as 
infection, non- healing, debridement or surgical revision 
of the stump wound, myocardial infarction, acute coro-
nary syndrome or arrhythmia not felt to be associated 
with toxicity to the Investigational Medicinal Product 
(IMP), pneumonia, pneumothorax, requirement for 
ventilation, tracheostomy, urinary retention, urinary tract 
infection, deep vein thrombosis, pulmonary embolism, 
stroke or transient ischaemic attack. These were consid-
ered as expected events which were causally unrelated to 
the IMP and trial intervention.
Data analysis
Analysis was carried out using SPSS 23.0 (descriptive 
statistics and non- parametric tests) and StataIC 13 (linear 
and logistic regression). Analysis was by intention- to- 
treat, with a planned secondary analysis of per- protocol 
treatment. All logistic and linear regression analyses were 
undertaken with the usual care arm as the reference 
and contained the following covariates: amputation type 
(above or below knee), sex (male or female), site (Royal 
Gwent Hospital or Morriston Hospital), patient age, 
opioid use at baseline, history of diabetes mellitus (yes or 
no), method of anaesthesia (with or without a continuous 
neuraxial anaesthetic infusion). The covariates included 
were agreed in the Statistical Analysis Plan by all members 
of the TMG and the TSC (who additionally held the role 
of an Independent Data Monitoring Committee). Where 
continuous outcomes could not be analysed using linear 
regression (even when transformed), a non- parametric 
Mann- Whitney U test was used to calculate a p value to 
assess the difference in medians between the two arms.
Sample size estimates
Sample size estimates for ordinal logistic regression ORs 
to achieve 90% power at the 5% significance level were 
estimated using the tool located at http://www. pmean. 
com/ 04/ OrdinalLogistic. html.36 No imputation of 
missing data was performed.
ethical and governance approval
The Trial Protocol was reviewed and approved by Wales 
Research Ethics Committee (REC) 3, recognised by the 
United Kingdom Ethics Committee Authority. Both 
hospital sites received Research and Development 
approval from the respective National Health Service 
Health Boards in Wales. A notice of no objection to the 
clinical trial notification was obtained from the Medicines 
and Healthcare products Regulatory Agency, and the trial 
was classified as a ‘type A’ Clinical Trial of Investigational 
Medical product, as both arms use procedures and medi-
cations which are already used in routine clinical practice.
Patient and public involvement
Patients and a lay representative have been integral in the 
design of PLACEMENT. Two lay representatives, one of 
whom is an amputee, have attended trial development 
and management meetings from inception and gave 
constructive input on the entire trial process. PLACE-
MENT was preceded by a public engagement group of 
amputees, led by an experienced qualitative researcher, 
to explore what factors were significant to amputees in 
the postoperative period, different experiences of postop-
erative pain relief (both with and without PNCs), and to 
explore if a trial examining PNC usage in the postopera-
tive period would be acceptable to patients.
reSultS
Screening, recruitment, retention and long-term follow up
A total of 50 patients were randomised between February 
2017 and November 2017 (figure 1). One hundred and 
three patients were screened for suitability, of whom 76 
(73.8%) were deemed eligible. The most frequent reasons 
for being ineligible were the inability to assess pain 
using a VRS (n=13) or the inability to provide informed 
consent due to incapacity (n=6). Of the 76 eligible 
patients, 54 (71.1%) provided written informed consent. 
The most frequent reasons for patients not providing 
consent were because the patient declined (n=8), a trial 
surgeon was unavailable (n=7) or there was inadequate 
time to consent (n=4). Four patients consented were not 
randomised due to a change in surgery type (n=3) or 
the trial surgeon being unavailable (n=1). One patient, 
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Figure 1 Consolidated Standards of Reporting Trials patient flow diagram. AKA, above knee amputation; BKA, below knee 
amputation; PVD, peripheral vasculardisease; MLLA, major lower limb amputation; VRS, Verbal Rating Scale.
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Table 1 Percentage of completion of pain assessment 
tools and opioid consumption preoperatively (baseline) and 
in the immediate postoperative period
OBAS n (%) Opioid use n (%) S- LANSS n (%)
Baseline 48 (96.0) 49 (98.0) 42 (84.0)
Day 1 41 (83.7) 48 (98.0) N/A
Day 2 40 (81.6) 48 (98.0) N/A
Day 3 36 (73.5) 48 (98.0) N/A
Day 4 38 (77.6) 48 (98.0) N/A
Day 5 45 (91.8) 48 (98.0) 41 (83.7)
N/A, not applicable; OBAS, Overall Benefit of Analgesia Score; 
S- LANSS, Self- completed Leeds Assessment of Neuropathic 
Symptoms and Signs scores.
Table 2 Percentage of completion rates at baseline, 2 and 6 months follow- up periods. No baseline Groningen data was 
captured
PLP (via Groningen) CSP (via Groningen) HADS anxiety HADS depression EQ- 5D
S- 
LANSS
Baseline (n=49) N/A N/A 90.0 94.0 96.0 84.0
2 months (n=45) 60.0 64.4 66.7 66.7 64.4 62.2
6 month (n=41) 34.2 43.9 41.5 41.5 43.9 39.0
CSP, chronic stump pain; HADS, Hospital Anxiety and Depression Scale;N/A, not applicable; PLP, phantom limb pain; S- LANSS, Self- 
completed Leeds Assessment of Neuropathic Symptoms and Signs scores.
randomised preoperatively, developed severe respiratory 
compromise during anaesthetic induction, and was subse-
quently deemed ineligible and therefore excluded from 
the trial. Forty- nine patients were therefore available for 
analysis.
Twenty- three of the 49 patients (46.9%) received the 
intervention. One patient randomised to usual care 
received a PNC, but the remaining 48 patients received 
the correct treatment allocation. Baseline demographics 
are presented in online supplementary table 1, and base-
line pain and opioid consumption data are presented 
in online supplementary table 2. No clinically relevant 
differences were noted in baseline pain or opioid usage 
between arms. The majority of patients were male (80%) 
with a mean age of 69.8 years. The BKA:AKA ratio was 
1.63. Baseline data completion rates on pain, opioid use, 
anxiety and depression and costs are given in table 1.
All patients completed 5 day follow- up. Although 45 
patients survived to 2 months, only 31 provided outcome 
data. At 6 months, 41 (82%) were alive and had not with-
drawn, but only 18/41 (39%) provided any outcome data.
Availability of primary effectiveness outcome data
There was significant missing data for the principle 
primary outcome, with 34 of 49 (69.4%) patients providing 
at least nine 11- point VRS pain scores. When these were 
transformed to the 4- point VRS and supplemented by 
routinely captured 4- point VRS, 45 of 49 (91.8%) patients 
provided at least nine pain scores and thus provided an 
alternative primary outcome.
Qualitative trial process interviews with healthcare 
professionals highlighted the difficulty in obtaining post-
operative pain scores, particularly out of hours, when 
there were no research nurses, and where nurse- captured 
4- point VRS scores were also sometimes missing. It was 
suggested that a reduction in the amount of data collected 
postoperatively would increase feasibility. Furthermore, 
both patients and healthcare professionals reported that 
using more than one pain scale was confusing for patients, 
with some giving conflicting scores across the two scales.
Availability of secondary outcome data
The completeness of data collection for other postopera-
tive variables is given in table 1 and the percentage of data 
completion at follow- up is given in table 2. Missing data 
at 2 and 6 month follow- up were high. This was despite 
making every effort to contact patients in person (if they 
were an inpatient locally at the time), via telephone and 
by postal questionnaires. The time frame for data capture 
was deliberately broad to try and improve responses. 
Response rates to postal questionnaires, when sent, was 
low (9 of 32). Nurses were not sent to patients’ home 
address to increase data capture as it was felt that this 
would be unsustainable in any future effectiveness trial.
Healthcare professionals identified in qualitative 
process evaluation interviews that capturing data at 6 
months was problematic as patients often could not be 
located; however, it was acknowledged that long- term 
follow- up is important to examine levels of chronic pain. 
It was highlighted that many of the follow- up questions 
could not be answered if patients were still in hospital. 
The time required to answer all questions was significant, 
and it was suggested that response rates might have been 
improved with less onerous data collection.
Primary effectiveness results and sample size calculations
The alternative primary effectiveness outcome was used 
for further analysis as described above. Forty- five of a 
possible 49 pain scores were recorded across both arms 
(table 3). Patients in the treatment arm appeared to expe-
rience less pain compared with the control arm (ordinal 
logistic regression OR 0.495, 95% CI 0.158 to 1.554). It 
was estimated that 207 patients would be required to 
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Table 3 Distribution of the alternative primary outcome by 
arm in the 45 patients providing data
Arm
Total n=45
Control arm 
n=23
Treatment 
arm n=22
n % n % n %
Pain 
outcome
None 11 47.8 14 63.6 25 55.6
Mild 6 26.1 5 22.7 11 24.4
Moderate 3 13.0 2 9.1 5 11.1
Severe 3 13.0 1 4.5 4 8.9
Table 4 Results of logistic regression on dichotomous secondary outcomes (post- surgery, discharge, month 2 and month 6)
Arm
OR 95% 
Control arm Treatment arm
N % N %
Treatment failure (post- surgery on day 0 
and the first five postoperative days)
No 3 12.0 6 26.1 0.571 0.165 to 1.975
Yes 22 88.0 17 73.9
Surgical site infection (at discharge) No 21 91.3 22 95.7 0.554 0.042 to 7.369
Yes 2 8.7 1 4.3
Nausea or vomiting (at discharge) No 17 73.9 21 91.3 0.249 0.042 to 1.487
Yes 6 26.1 2 8.7
Month 2 chronic stump pain Absent 8 66.7 14 82.4 0.228 0.012 to 4.525
Present 4 33.3 3 17.6
Month 2 phantom limb pain Absent 7 58.3 11 73.3 0.158 0.015 to 1.623
Present 5 41.7 4 26.7
Month 6 chronic stump pain Absent 6 66.7 7 77.8 0.137 0.006 to 3.015
Present 3 33.3 2 22.2
Month 6 phantom limb pain Absent 5 71.4 4 57.1 2.286 0.142 to 36.808
Present 2 28.6 3 42.9
achieve 90% power at the 5% level to detect a difference 
in pain similar to this feasibility study, allowing for 10% 
loss of primary outcome data.
Qualitative interviews with patients in the treatment 
arm suggested they valued the localised and continuous 
nature of the PNC, feeling reassured that their pain would 
be managed well.
Other effectiveness results
Multiple secondary effectiveness results were analysed. 
Details of treatment failure, CSP, PLP, SSI, nausea and 
vomiting, S- LANNS, opioid use, OBAS, anxiety (from 
HADS) and depression (from HADS) are given in tables 4 
and 5. Significant missing data at follow- up resulted in 
wide CIs for estimated effect sizes. Nerve identification 
and successful placement of the PNC was 100%.
trial acceptability and understanding
Qualitative interview data indicated that patients found 
trial processes acceptable and were happy with the 
randomisation aspect of the trial. Healthcare profes-
sionals reported that patients who consented to take 
part understood the trial information provided, and that 
written trial information was clear and of a suitable level. 
Despite this, the majority of patients did not demonstrate 
a good understanding of the trial at the time of inter-
view, particularly randomisation processes. Interviewees’ 
ability to give an accurate account of trial information 
may have been affected by difficulty recalling information 
given preoperatively rather than a lack of understanding. 
However, thoroughly checking patient understanding at 
the time of consent will be an important consideration 
for future trials in this area.
Some healthcare professionals felt that it was preferable 
from a pain management perspective for patients to be in 
the intervention arm. Therefore, reassurance that pain 
will be managed effectively for these patients would be 
key for future trials to ensure engagement and equipoise.
health economic analysis
The costs associated with the PNC were estimated at £130 
per participant (online supplementary table 3). Mean 
length of postoperative stay was approximately equivalent 
between the two arms (inpatient stay until medically fit 
for discharge: treatment arm (mean±SD) 24.43±21.28 
days; usual care: 24.05±18.46 days). Based on available 
cases the pattern of healthcare resource use over 6 
months was similar for both groups, with hospital admis-
sions (elective and non- elective), out- patient attendance 
and primary care (district nurse and general practitioner 
consultations) being the key drivers of resource use 
(online supplementary table 4). Resource use data were 
highly skewed, with baseline differences between the two 
arms evident. Similar to the issues of attrition identified 
for collection of other patient- reported data at follow- up 
above (table 2), there was evidence of significant missing 
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Table 5 Descriptives and results of non- parametric Mann- Whitney U (MWU) tests or linear regression on continuous 
secondary outcomes (post- surgery, day 5, month 2 and month 6)
Arm
P value 
(MWU)
Control arm Treatment arm
N Median
IQR
N Median
IQR
LB UB LB UB
Day 5 S- LANSS 21 12.0 3.0 14.0 20 6.5 0.0 13.5 0.331
Month 2 S- LANSS 12 0.0 0.0 6.0 16 5.0 2.0 11.0 0.159*
Month 6 S- LANSS 8 9.0 1.0 13.0 8 10.0 2.5 16.5 0.721*
Opioid Use (first five 
postoperative days)
25 12.2 7.0 22.5 23 8.0 3.0 21.0 0.302
n Mean SD n Mean SD Difference 
in means
95% CI
OBAS (first five 
postoperative days)
24 3.4 2.57 23 3.0 2.54 N/A N/A
Natural log of OBAS 24 1.3 0.57 23 1.2 0.63 −0.220 −0.528 to 
0.087
Month 2 HADS 
depression score
13 7.2 5.79 16 5.8 3.55 −1.912 −4.549 to 
0.725
Month 6 HADS 
depression score
8 7.9 6.60 7 8.0 2.89 −1.211 −4.099 to 
1.676
NB: For S- LANNS, a higher score indicates that pain is more neuropathic.
*Exact, rather than asymptotic, p value displayed based on algorithm of Dineen and Blakesley.
HADS, Hospital Anxiety and Depression Scale; IQR, interquartile range; LB, lower bound;N/A, not applicable; OBAS, Overall Benefit of 
Analgesia Score; SD, standard deviation; S- LANSS, Self- completed Leeds Assessment of Neuropathic Symptoms and Signs scores; UB, 
upper bound.
data for the patient- reported resource use questionnaire. 
Limited data obtained on direct and indirect costs to the 
patient and family precluded formal examination.
DISCuSSIOn
The PLACEMENT trial has demonstrated that recruit-
ment into a randomised controlled trial comparing PNC 
use to standard care was feasible. Recruitment rates were 
excellent, with over 60% of all eligible patients being 
recruited. Patients and healthcare professionals found 
trial processes acceptable. Nerve identification and 
PNC placement rates were 100%. Using the alternative 
primary outcome, over 90% of patients provided enough 
primary outcome data. Attrition rates were very high at 2 
and 6 month follow- up and need to be accounted for in 
any future effectiveness trial.
Patients undergoing amputation for PVD are often 
comorbid and suffer with cognitive impairment.37 It is 
unsurprising that the most frequent reason for ineligi-
bility at screening is due to a lack of mental capacity. Of 
the 76 eligible patients, 49 were recruited. This propor-
tion (64.5%) is in line with the results of a recent review 
of 151 Health Technology Assessment (HTA) funded 
RCTs, reporting a proportion of 70% (IQR 51% to 87%) 
of successfully completed trails.38
We chose the 11- point VRS as the tool to provide our 
principle primary outcome as it is recommended by 
multiple studies of pain measurement.31 During trial 
set- up, we identified it may be difficult to capture a signifi-
cant number of measurements using this scale, which is why 
we also recorded routinely collected 4- point VRS measure-
ments. Only 69.4% of patients provided principle primary 
outcome data, whereas over 90% of patients supplied alter-
native primary outcome data, which used the routinely 
collected 4- point VRS score. Admittedly this is using an 
arbitrarily definition of ‘sufficient data’ (greater that 50% 
completion rate), as defined by the TMG. However, this 
is in line with outcome data rates from the HTA review of 
successful trials (89%, IQR: 79% to 97%), supporting use 
of the alternative primary outcome in a future effectiveness 
trial.38 Any future trial should aim to use whichever pain 
scale is routinely collected in the trial centre, with all data 
then converted to the 4- point scale for analysis.
Attrition rates at follow- up were markedly high. It is well 
recognised that amputees suffer high rates of mortality, 
with figures from some studies as high as 50% at 1 year. 
While death accounted for only eight patients (16.3%) at 
6 months, several other patients were hospitalised for other 
medical problems, still in rehabilitation centres, or other-
wise uncontactable. While not necessarily unsurprising, 
the difficulty with obtaining patient- reported data at 2 and 
6 month follow- up limit the ability to investigate the effect of 
postoperative PNC usage on PLP and CSP. There have been 
relatively few randomised trials recruiting amputees, and 
the long- term attrition rates found here will be important 
to consider in any future trials.
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Assessing postoperative pain is not standardised or straight-
forward. No clear guidelines exist for specifying which tool, at 
what frequency should be used nor how it should be analysed. 
It is also not clear how best to adjust for baseline/preoper-
ative pain. A systematic review published in 2011 identified 
54 papers comparing different tools for assessing postoper-
ative pain, of which 52 used Visual Analogue Scale, 39 used 
VRS and 32 a numerical rating scale.39 Use of a numerical 
rating scale had better compliance in the majority of studies 
reporting this, and was the recommended tool in 11 of the 
studies. A more recent systematic review of postoperative 
pain reporting after regional analgesia identified 15 different 
outcome measures used in 31 different studies, with some 
including pain on movement as well as at rest.40 Five studies 
recorded maximal pain score during the study period. This 
heterogeneity in reporting is a problem in many disciplines, 
and the COMET (Core Outcome Measures in Effective-
ness Trials) group aims to standardise reporting of outcome 
measures. While a core outcome set for chronic pain has 
been published, none exist for postoperative pain.31
A number of tools were used to assess pain other than the 
VRS. The S- LANNS scores were captured at day 0 and 5, and 
at 2 and 6 months. S- LANSS is a tool predominantly used for 
differentiating between nociceptive and neuropathic pain in 
patients with chronic pain, and its use and value in the imme-
diate postoperative period is uncertain. Completion rates were 
approximately 84%, so it may be useful to identify pain type, 
but whether this is of prognostic value remains unknown. The 
OBAS tool was developed for use in the postoperative period 
and attempts to capture a quantitative measure of overall 
patient satisfaction with analgesia. While the composite score 
contains a rating for current pain experience, it is heavily 
weighted towards the side effects of opioid analgesia. Comple-
tion rates were reasonable, but it lacked discriminatory power 
in this study, with minimal between- group differences. Long- 
term CSP and PLP were assessed by the Groningen question-
naire, although these data were subsequently dichotomised 
using an arbitrarily decided division point. This approach 
makes the data easier to quantify and interpret, but fails to 
account for degree of pain, or episodic but very severe pain,
Addressing the cost- effectiveness of PNC as a secondary 
objective is feasible in a future effectiveness trial, but a 
number of design issues would need to be considered. The 
challenge of obtaining resource use data could be resolved 
by capturing this information as part of the clinical trial 
record, with key drivers such as hospital admission collected 
from routine records. While the EQ- 5D is a well- established 
measure to derive utilities, the challenges of baseline imbal-
ance, missing data and lack of sensitivity are important 
considerations for a future trial- based economic analysis. 
Postoperative PNC use is, by definition, a short- term inter-
vention, and longer- term QoL- related utility differences 
are unlikely to be large. Economic evaluation of PNC use, 
costing only £130 to administer, should most likely focus on 
demonstrating non- inferiority rather than superiority in an 
effectiveness study.
Qualitative interviews proved an invaluable addition to 
the feasibility process. The difficulty in deciding on a pain 
assessment tool was noted by the TMG. While no clear 
consensus emerged in our interviews with patients and 
healthcare professionals as to which tool was preferred, it 
was noted that using more than one pain scale was confusing 
for patients. Future trials should therefore consider using 
whichever pain tool is already used at their institution. Inter-
views also identified a lack of patient understanding of the 
trial. Our experience is that patients undergoing amputa-
tion often have mild cognitive impairment, and we suggest 
this finding may represent a lack of patient recall, rather 
than inadequate consent technique. Issues around patient 
understanding of the informed consent process have been 
reported previously. For example, the systematic of Falagas 
et al41 found that adequate understanding of the randomi-
sation process by patients was demonstrated in only 50% 
of the studies providing relevant data. Any future efficacy 
trial would need to take account of this specific issue and, 
after careful discussion with patients, decide on approaches 
to maximise patient understanding and retention of trial 
information. This may include the use of interventions with 
evidence of efficacy,42 including multimedia content of the 
trial process, and an extended discussion for consent.
One potential limitation of this study is that it did not 
assess the use of a placebo arm, with infusion of a non- active 
substance. ‘Soft’ outcomes such as pain scores are known 
to be susceptible to the placebo effect, so any benefit seen 
in the treatment arm could be a result of this.43 However 
it could be argued that even if the effect of the perineural 
catheter is not mediated by the local anaesthetic nerve 
blockage, if it is shown to be of benefit over usual care 
then this is a result which is likely to translate into clinical 
practice, so is still of value. We therefore feel that the prag-
matic design of simply comparing placement and use of the 
PNC to usual care is appropriate. Placebo interventions in 
surgical trials are also well recognised as being difficult, and 
face ethical issues over and above medical trials.44
COnCluSIOn
This study has shown that recruitment to an RCT evalu-
ating the effectiveness of a PNC on postoperative pain in 
amputees is feasible, with recruitment rates comparable 
to recently completed efficacy trials. Immediate postop-
erative pain was more efficiently captured using a 4- point 
VRS than with an 11- point VRS. Opioid consumption is also 
well captured. Significant attrition should be expected and 
planned for, which could limit investigation into the effects 
of PNC usage on PLP and CSP.
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